Vaxcine(TM): an oil-based adjuvant for influenza vaccines

• Published in: Memórias do Instituto Oswaldo Cruz Vol. 106; no. 8; pp. 1052 - 1054
• Main Authors: Alves, Rosely Cabette Barbosa, New, Roger Randal Charles, Andrade, Gabrielle Ribeiro, Mendonça, Rita Maria Zucatelli, Sant'Anna, Osvaldo Augusto Brasil Esteves, Mancini, Dalva Assunção Portari, Silva-Junior, Silvio Marciano da, Domingos, Marta de Oliveira
• Format: Journal Article
• Language: English
• Published: Brazil 01-12-2011
• Subjects: Adjuvants, Immunologic - therapeutic use; Animals; Antibodies, Viral - blood; Antibodies, Viral - immunology; Female; Hemagglutination Inhibition Tests; Immunoglobulin G - blood; Immunoglobulin G - immunology; Influenza A Virus, H3N2 Subtype - immunology; Influenza Vaccines - therapeutic use; Mice; Mineral Oil - therapeutic use; Orthomyxoviridae Infections - immunology; Orthomyxoviridae Infections - prevention & control
• ISSN: 1678-8060
• DOI: 10.1590/S0074-02762011000800026

Vaccination is the method of choice for the prevention of influenza infection. However, the quantity of the antigen available, especially in the case of pandemics, often fails to meet the global demand. However, improved adjuvants can overcome this problem. Preliminary results obtained in this study revealed that one year after a single subcutaneous immunisation with influenza A H3N2 virus in an oil-based carrier, Vaxcine(TM), outbreed mice produced a high immunoglobulin G response that lasted for up to one year and exhibited less variation in titre compared with the response of the control group treated with alum. The haemagglutination-inhibition titres induced by Vaxcine(TM) were also higher than those generated by alum. These data indicate that Vaxcine(TM) is a good adjuvant candidate for seasonal influenza vaccines.